Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
646
Completed, industry sponsors, Respiratory, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed646
646 trials
Showing 1 to 25, recently updated first.
Clarametyx Biosciences, Inc.Industry
NCT06159725 · 43 participants · Start Jun 24, 2024 · Primary completion Nov 14, 2025
Drug: CMTX-101; Placebo · For: Persistent Infection; Cystic Fibrosis
Sites: Birmingham, Alabama; Palo Alto, California; San Franciso, California · 23 sites in all
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With BronchiectasisPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT06166056 · 108 participants · Start Nov 29, 2023 · Primary completion Aug 27, 2026
Drug: CHF6333; CHF6333 Placebo · For: Bronchiectasis
Sites: Cambridge, United Kingdom; Dundee, United Kingdom; Edinburgh, United Kingdom · 8 sites in all
AeroRx Therapeutics Inc.Industry
NCT07802730 · 24 participants · Start Sep 21, 2026 · Primary completion Oct 9, 2026
Drug: AERO-002 (60 mcg); Glycopyrrolate (18 mcg) · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Manchester, United Kingdom
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05668741 · 26 participants · Start Feb 27, 2023 · Primary completion Apr 21, 2026
Drug: VX-522 mRNA therapy; IVA · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Long Beach, California; Palo Alto, California · 26 sites in all
AJU Pharm Co., Ltd.Industry
NCT07231861 · 62 participants · Start Dec 12, 2025 · Primary completion Dec 21, 2025
Drug: AJU-R713; R713R · For: Bronchial Asthma; Perennial Allergic Rhinitis
Sites: Seoul, South Korea
- Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.Pivotal-lookingCompleted
Sionna Therapeutics Inc.Industry
NCT07035990 · 120 participants · Start Jul 23, 2025 · Primary completion Mar 23, 2026
Drug: SION-451; SION-2222 and 4 more · For: Cystic Fibrosis (CF)
Sites: Brisbane, Australia; Melbourne, Australia
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07116915 · 85 participants · Start Aug 11, 2025 · Primary completion Aug 14, 2026
Drug: HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension; HRS-9821 Powder for Inhalation placebo/HRS-9821 inhalation suspension placebo and 1 more · For: COPD
Sites: Chengdu, China
Shanghai Xin Huanghe Pharmaceutical Co., Ltd.Industry
NCT07804303 · 30 participants · Start Jan 13, 2024 · Primary completion Jan 22, 2024
Drug: Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Test); Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference) · For: Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Sites: Nanjing, China
PfizerPfizer (PFE)
NCT06137742 · 97 participants · Start Nov 17, 2023 · Primary completion Jul 31, 2026
Drug: PF-07868489; Placebo for PF-07868489 · For: Pulmonary Arterial Hypertension
Sites: Anaheim, California; Costa Mesa, California; Orange, California · 46 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06702462 · 20 participants · Start Mar 11, 2025 · Primary completion Jun 4, 2025
Drug: HFA-152A propellant; HFA-134A propellant · For: Asthma
Sites: Marlton, New Jersey; Huntersville, North Carolina; San Antonio, Texas
Reistone Biopharma Company LimitedIndustry
NCT07289464 · 48 participants · Start Jan 8, 2026 · Primary completion Aug 10, 2026
Drug: RSS0343 Tablets; RSS0343 Tablets Placebo · For: Non-cystic Fibrosis Bronchiectasis
Sites: Wuhan, China
PureTechIndustry
NCT06717100 · 24 participants · Start Dec 17, 2024 · Primary completion Feb 17, 2025
Drug: Nintedanib 150 MG [Ofev] · For: Drug Interactions
Sites: Melbourne, Australia
- A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06748079 · 113 participants · Start Dec 3, 2024 · Primary completion Aug 7, 2026
Drug: TQC3721 inhalation powder; Placebo for TQC3721 inhalation powder and 1 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Chengdu, China
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic FibrosisPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06154447 · 165 participants · Start Dec 12, 2023 · Primary completion Jul 10, 2026
Drug: VX-828; Placebo and 7 more · For: Cystic Fibrosis
Sites: Hollywood, Florida; Orlando, Florida; Overland Park, Kansas · 12 sites in all
- Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
Arrowhead PharmaceuticalsIndustry
NCT05537025 · 105 participants · Start Jan 30, 2023 · Primary completion Sep 5, 2025
Drug: ARO-MMP7 Inhalation Solution; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Copenhagen, Denmark; Odense, Denmark; Ancona, Italy · 19 sites in all
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT06290102 · 30 participants · Start May 16, 2024 · Primary completion Oct 1, 2024
Drug: TEV-56248; Fp MDPI · For: Asthma
Sites: Mobile, Alabama; Long Beach, California; Miami, Florida · 10 sites in all
Trevi TherapeuticsIndustry
NCT07036029 · 9 participants · Start Aug 21, 2025 · Primary completion Jun 30, 2026
Drug: NAL ER; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Rochester, Minnesota; Manchester, United Kingdom
Wuhan Optics Valley Vcanbiopharma Co., Ltd.Industry
NCT06230822 · 9 participants · Start Mar 5, 2024 · Primary completion Mar 13, 2025
Drug: VUM02 Injection · For: Idiopathic Pulmonary Fibrosis
Sites: Beijing, China; Chengdu, China; Guangzhou, China · 4 sites in all
Mannkind CorporationIndustry
NCT07344558 · 27 participants · Start Dec 22, 2025 · Primary completion Jun 17, 2026
Drug: MNKD-201(Nintedanib DPI); Placebo · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Fresno, California; Palm Springs, California; Doral, Florida · 9 sites in all
Genosco Inc.Industry
NCT07225296 · 63 participants · Start Nov 12, 2025 · Primary completion Jun 30, 2026
Drug: GNS-3545; GNS-3545 Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Baltimore, Maryland
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06821464 · 45 participants · Start Feb 17, 2025 · Primary completion Jul 27, 2025
Drug: HRS-9813; HRS-9813 · For: Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis
Sites: Shanghai, China
Respirion Pharmaceuticals Pty LtdIndustry
NCT06016088 · 71 participants · Start Apr 1, 2024 · Primary completion Apr 15, 2026
Drug: RSP-1502; Tobramycin inhalation solution · For: Cystic Fibrosis Lung; Respiratory Infections, Recurrent, Chronic; Pseudomonas Aeruginosa
Sites: Tucson, Arizona; Los Angeles, California; Palo Alto, California · 22 sites in all
- Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPFPivotal-lookingCompleted
Agomab Spain S.L.Industry
NCT06181370 · 143 participants · Start Dec 1, 2023 · Primary completion Apr 29, 2026
Drug: AGMB-447 · For: IPF
Sites: Manchester, United Kingdom
- A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult ParticipantsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05602025 · 140 participants · Start Dec 13, 2022 · Primary completion Oct 23, 2023
Drug: Depemokimab · For: Asthma
Sites: Orlando, Florida; Las Vegas, Nevada; Austin, Texas
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06947408 · 44 participants · Start May 14, 2025 · Primary completion May 11, 2026
Drug: Placebo; IBI3002 · For: Asthma
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.